PuSH - Publication Server of Helmholtz Zentrum München: Kombination Radio(chemo)therapie beim Lungenkarzinom

Information

Clues to quality of journals

Open Access Policy of Helmholtz Association 2016

CC Licencences

Publication Metrics

Navigation

Home

Deutsch

EVA: Electronic Publishing

New EVA Application

Research

Advanced Search

Browse by ...

... HMGU-Authors/Consortia

... Organizational Structure

... Journal

... Publication Type

... Research Data

... Arbeitsgruppen

... Publication Year

Publication overview

Statistics

Statistics (last 5 years)

OA Publications

Publish

Submit Publication

Import publication from...

...EVA

Report missing publication

Highlights

Support & Contact

Contact persons

Help

Data protection

Helmholtz Open Science

JANE Journal Estimator

SHERPA/RoMEO

DOAJ

Export:

Text

Endnote (RIS) BIB

BibTeX

Kraus, K.M. ; Eichner, R.* ; Combs, S.E.

Kombination Radio(chemo)therapie beim Lungenkarzinom – Nebenwirkungsmanagement.

Combined chemoradiotherapy in lung cancer—Management of side effects.

Best Pract. Onkol. 18, 496-507 (2023)

Publ. Version/Full Text

DOI

	Closed

Open Access Green as soon as Postprint is submitted to ZB.

Abstract
Metrics
Extra information

Simultaneous chemoradiotherapy (CRT) is the standard treatment for locally advanced non-small cell lung cancer (NSCLC) in stage III and for limited stages of small cell lung cancer (SCLC) and nonoperability. The side effects depend on the cytotoxic agents employed, the radiotherapeutic parameters and the patient characteristics. This article summarizes and discusses the management strategies for frequent and relevant side effects of CRT of lung cancer. The chemotherapy mostly includes a highly emetogenic platinum derivative. Therefore, prophylaxis of chemotherapy-associated nausea and vomiting with serotonin 5‑hydroxytryptamine‑3 (5-HT3) and neurokinin 1 (NK1) receptor antagonists and dexamethasone is an essential element of peritherapeutic management. The management of likewise primary chemotherapy-induced hematologic side effects depends on the severity and the affected blood cell lineage and involves growth factors and blood transfusions. In contrast, radiotherapy-induced alterations, especially of the lungs and esophagus can mostly not be causally treated but are treated symptomatically. The prophylaxis and treatment of the broad spectrum of side effects of CRT of lung cancer should be based on a thorough evaluation of the severity of symptoms, the treatment efficacy and associated risks.

Impact Factor

Scopus SNIP

Altmetric

0.000

0.012